X4 Pharmaceuticals (NASDAQ:XFOR) reported its fourth-quarter and full-year 2025 financial results on March 17, 2026, marking a year of transition from a clinical-stage entity to a commercial-revenue-generating firm.
The company achieved total revenue of $35.1 million for the year, comprised of $6.5 million in initial product sales and $28.6 million in licensing revenue.
While the company reported an annual operating loss of $86.9 million and a net loss of $79.2 million, management emphasized that 2025 served as a foundation for long-term scaling.
A primary highlight of the corporate update was the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) for mavorixafor in the treatment of WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome.
This favorable European regulatory stance significantly de-risks the path toward a formal marketing authorization in the EU, following the drug's earlier approval in the United States.
Furthermore, the company remains on schedule with its global 4WARD Phase 3 clinical trial, which is evaluating mavorixafor for chronic neutropenia; enrollment is expected to reach completion by the third quarter of 2026.
Financially, X4 Pharmaceuticals enters 2026 in its strongest liquidity position to date.
The company reported a cash and equivalents balance of $253 million as of December 31, 2025.
According to management, this capital is sufficient to fund all planned operations, clinical milestones, and commercial expansion efforts through 2028.